Mount Sinai Developing `End-to-End` Diagnostics Solution for COVID-19

For patients who test positive for SARS-CoV-2, a quantitative assay designed and implemented by a multidisciplinary Mount Sinai team is capable of measuring whether the patient’s viral load is high or low. The viral load findings will be studied to ascertain whether they assist in managing the disease and aiding in the selection of effective treatments.

Additionally, a team of ISMMS researchers has developed a serological enzyme-linked immunosorbent assay (ELISA) test which measures the presence or absence of antibodies to the virus in people’s blood. The test shows whether a person’s immune system has ever come into contact with the virus (even months ago), thus providing an accurate picture of how many people have been infected; identifying people with new immunity to SARS-CoV-2 who could care for COVID-19 patients at zero or minimal risk; and identifying newly-recovered patients with high antibody levels who can donate their antibody-rich blood, known as convalescent plasma, to potentially save other patients with severe COVID-19.

The test was developed by cloning animal cells to produce copies of the telltale “spike” protein that is present on the surface of SARS-CoV-2. The protein is highly immunogenic, which means that people’s bodies see it and begin making antibodies that can lock onto it. The test involves exposing a sample of blood to bits of the spike protein. If the test “lights up,” it means that person has the antibodies. The sensitive and specific identification of SARS-CoV-2 that ELISA provides will also support screening of health care workers to identify those who have already been exposed and are already immune.

Meanwhile, another team of Mount Sinai researchers are working on a test called the Ella Cytokine Storm Panel to determine when someone infected with COVID-19 is entering a critical point in their disease. This burst of cytokines, called cytokine release syndrome or a “cytokine storm,” contributes to the severity of COVID-19, because the cytokines attack the patient’s organs, which can be fatal in some cases. Mount Sinai clinical laboratories will use the Ella Cytokine Storm Panel in COVID-19 patients who have been admitted to the hospital to monitor them and know, in real time, when they are experiencing cytokine storm. The test results are available in a few hours, and can be repeated throughout the course of care to help guide hospital care and to measure the response to experimental drugs given in clinical trials for COVID-19 patients.

“Some of the best researchers in the world, giants on the frontier of the fields of infectious disease, microbiology, emerging pathogens, and immunology, are here at the Icahn School of Medicine at Mount Sinai and The Mount Sinai Hospital. Since the COVID-19 pandemic began, they have been tracking the data coming out of China and Italy to mount a response that will help diagnose and treat ill patients,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System. “Our health system has fast-tracked funding and approvals for these tests and clinical trials to help patients not just within our own community, but to help people around the globe.”

Related Links:
Icahn School of Medicine at Mount Sinai
The Mount Sinai Hospital